Evidence map›Paper›PMID 31357550›Full record

ArticleGenes2019

Kinetic Modeling of DUSP Regulation in Herceptin-Resistant HER2-Positive Breast Cancer.

Petronela Buiga, Ari Elson, Lydia Tabernero, Jean-Marc Schwartz

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Dual-specificity phosphatases: therapeutic targets in cancer therapy resistance.Journal of cancer research and clinical oncology · 2022
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Petronela BuigaSchool of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester M13 9PT, UK.
Ari ElsonDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel.
Lydia TaberneroSchool of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester M13 9PT, UK.
Jean-Marc SchwartzSchool of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester M13 9PT, UK. jean-marc.schwartz@manchester.ac.uk.
Manchester Academic Health Science Centre · GBWeizmann Institute of Science · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHER2 (human epidermal growth factor 2)-positive breast cancer is an aggressive type of breast cancer characterized by the overexpression of the receptor-type protein tyrosine kinase HER2 or amplification of the

Indexed as

Drug Resistance, NeoplasmAntineoplastic Agents, ImmunologicalBreast NeoplasmsCell Line, TumorDual-Specificity PhosphatasesErb-b2 Receptor Tyrosine KinasesFemaleHEK293 CellsHumansMAP Kinase Signaling SystemModels, TheoreticalTrastuzumabAntineoplastic Agents, ImmunologicalDual-Specificity PhosphatasesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesTrastuzumabbreast cancerdual-specificity phosphatasesHerceptinkinetic model

Identifiers

PMID31357550
PMCPMC6723192
OpenAlexW2963077029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.